Large Market
Companion Diagnostics (CDx) is a $4B annual business with 90% of CDx in oncology.
Personalized Approach
Developing a diagnostic that finds patients that will respond to a particular drug is crucial in targeted therapies and personalized medicine.
Identify & Inhibit
We have demonstrated a CDx that identifies cancers that express ASCT2 and can provide insight to level of ASCT2 expressed. ASCT2 is the glutamine transporter our compound inhibits.
A Novel GTI PET Tracer for Early Lung Cancer Diagnostics: Animal Model
